Method and device for predicting non-small cell lung cancer prognosis based on tumor infiltration edge E-TLS
By extracting the E-TLS density characteristics and immune cell characteristics at the edge of tumor infiltration, combined with TNM staging, the problem of NSCLC prognosis judgment was solved. It was found that the high expression of E-TLS in the IM region is closely related to the patient's prognosis, providing new prognosis evaluation indicators and Immunotherapy reference.
Patent Information
- Application Number
- CN202411011194.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively predict the prognosis of non-small cell lung cancer (NSCLC), especially in early diagnosis, imaging and serological marker diagnostic efficacy, and the relationship between the expression and prognosis of tumor-infiltrating marginal immune cells is not clear.
By obtaining tumor histopathological sections, locate and extracting the E-TLS density characteristics at the edge of tumor infiltration, the classifier is used to judge the patient's prognosis, determine the E-TLS density threshold, and combine TNM staging and immune cell characteristics to input it into the classifier for prognosis judgment.
By subdividing tumor areas in a refined manner, it was found that high expression of E-TLS in IM area is related to poor prognosis, suggesting the important role of IM area in tumor immunity and providing a reference for the improvement of immunotherapy and survival prediction of NSCLC.
Smart Images

Figure CN119007982A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of intelligent medical treatment, and more specifically, to a method, device, medium and program product for predicting the prognosis of non-small cell lung cancer based on tumor infiltration margin E-TLS. Background Art
[0002] Lung cancer is the second most common cancer worldwide. Among lung cancers, NSCLC (non-small cell lung cancer) accounts for more than 85% of the total number of lung cancer cases. Analysis of the reasons for the low survival rate of NSCLC shows that NSCLC itself lacks specific clinical symptoms and manifestations in the early stage, and the commonly used clinical imaging examinations often miss some early lung nodules or cannot give a clear diagnosis of lung cancer. At the same time, the diagnostic efficacy of serological tumor markers that can be used for lung cancer screening is low. Therefore, NSCLC is often discovered in the middle and late stages.
[0003] Traditional treatments for lung cancer include surgical resection, radiotherapy, and chemotherapy. In recent years, with the in-depth study of TIME (tumor immune microenvironment), immunotherapy has been applied to the treatment of NSCLC. The occurrence and development of lung cancer is inseparable from the surrounding TIME. TIME includes a large number of immune cells, which interact with each other and with tumor malignant cells to form a complex heterogeneous network. A large number of experiments have been carried out on the functional analysis of TIME components. Studies have shown that the massive infiltration of lymphocytes and CD68+ macrophages, mainly CD20+B cells and CD8+T cells, is usually significantly associated with better progression-free survival and overall survival in NSCLC patients, while the massive expression of immunosuppressive cells such as Treg cells is associated with worse clinical outcomes in patients. In addition, a spatial genomic analysis of TIME in breast cancer patients found that scattered immune cells and ordered immune cell aggregation structures in tumors have functional differences in regulating tumor immunity.
[11] The ordered structure of this type of immune cells is called TLS (tertiary lymphoid structure). The density and structure of immune cells in tumor-related TLS may be related to the patient's clinical outcome. And with the deepening of research, more and more scholars have realized the important value of TLS in tumor immunity.
[0004] TLS is an organized lymphoid aggregate formed on the network after CD8+T cells induce fibroblasts to form a reticular structure. It is mainly composed of T cell (CD3+) colonies surrounding B cell (CD20+) colonies, with macrophages, dendritic cells, other stromal cells and high endothelial venules distributed on the periphery. TLS was first discovered in inflammation-related tissues and is named because its structural components resemble secondary lymphoid organs. When the body is infected, TLS can form rapidly at the infected site and play an immune protective role. In recent years, the presence of TLS in many types of tumor tissues such as liver cancer, colorectal cancer, and lung cancer and its correlation with prognosis have been reported. Further studies have found that TLS exists in different maturation states, and its expression in tumors and its effect on prognosis are also different. Mature TLS, also known as secondary / follicular TLS, has the same GC (growth center) as secondary lymphoid organs, and its core component is follicular dendritic cells (CD21+). Mature TLS are important sites for initiating or maintaining local and systemic B and T cell responses to tumors. When mature TLS containing GCs are abundant in tumor tissues, they are associated with hepatocellular carcinoma.
[22] , colorectal cancer, pancreatic cancer, pancreatic neuroendocrine tumors, NSCLC, oral cancer and other tumors. The increase in immature TLS in the tumor, also known as primary TLS (without GC), may be associated with poor patient prognosis. At present, the expression of TLS in different areas of NSCLC tumors, the correlation between TLS expression and infiltrating immune cells in the tumor, and the relationship with patient prognosis are not clear. Therefore, it is necessary to further explore the correlation between TLS expression and patient prognosis, aiming to provide a reference for the improvement of NSCLC immunotherapy and provide new risk assessment indicators for survival prediction of NSCLC patients. Summary of the invention
[0005] In view of the above problems, the present invention provides a method for predicting the prognosis of non-small cell lung cancer based on tumor infiltration margin E-TLS, which uses data processing and feature extraction to capture information in time series data, and proposes improvements to the parameters of the disease prediction model and performs effective optimization, thereby constructing a disease warning model suitable for clinical use.
[0006] The present application (first aspect) discloses a method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS, comprising:
[0007] S101: Obtain tumor tissue pathological sections from patients with non-small cell lung cancer;
[0008] S102: locating the tumor infiltration edge of the tumor tissue pathological section;
[0009] S103: extracting the E-TLS density feature of the tumor invasion edge;
[0010] S104: Determine the prognosis of a patient with non-small cell lung cancer according to the E-TLS density feature of the tumor infiltration edge. If the E-TLS density feature is lower than the E-TLS density threshold, the patient's prognosis is good; if the E-TLS density feature is higher than the E-TLS density threshold, the patient's prognosis is poor.
[0011] Further, the step of determining the E-TLS density threshold comprises:
[0012] Step 1: Obtain tumor tissue pathology sections of a patient set of non-small cell lung cancer; and obtain the overall survival of the patient set of non-small cell lung cancer;
[0013] Step 2: Locate the tumor infiltration margin of the tumor tissue pathology section;
[0014] Step 3: extracting the E-TLS density feature set of the tumor invasion edge;
[0015] Step 3: Plot a ROC curve of the relationship between the E-TLS density feature set and the overall survival period, and the E-TLS density threshold is the optimal cutoff value of the ROC curve.
[0016] Furthermore, the TNM staging of non-small cell lung cancer patients is simultaneously obtained in 101, and S104 is replaced by S104': the E-TLS density feature and the TNM staging are input into a classifier, and the prognosis of the non-small cell lung cancer patient is determined according to the output of the classifier.
[0017] Furthermore, the S103 also includes extracting immune cell characteristics of the tumor infiltration edge, and the immune cell characteristics of the tumor infiltration edge include one or more of the following: CD20+B cell density, CD8 / CD3 cell density ratio, CD3+T cell density; the S104 is inputting the E-TLS density characteristics, TNM staging and the immune cell characteristics of the tumor infiltration edge into a classifier, and judging the prognosis of patients with non-small cell lung cancer according to the output of the classifier.
[0018] Furthermore, the outside of the tumor of the tumor tissue pathological section is simultaneously located in S102, and the S103 also includes extracting the CD20+B cell density outside the tumor; and the 104 is inputting the E-TLS density feature, TNM staging, the immune cell feature of the tumor infiltration edge, and the CD20+B cell density outside the tumor into a classifier, and judging the prognosis of patients with non-small cell lung cancer according to the output of the classifier.
[0019] Further, the step of extracting the E-TLS density feature of the tumor invasion edge includes:
[0020] Performing immunohistochemical staining on the tumor tissue pathology section and then scanning to obtain a stained tumor tissue pathology section image;
[0021] The E-TLS density feature is obtained based on the extraction of the stained tumor tissue pathological section image;
[0022] Optionally, a specific antibody is used to perform immunohistochemical staining on different cell components in the tumor tissue pathology section and then scanned to obtain a stained tumor tissue pathology section image, wherein the immunohistochemical staining is IHC staining, and the different cell components include CD3+T cells and CD20+B cells. The E-TLS area is identified according to the stained tumor tissue pathology section image and the E-TLS density feature is calculated; the E-TLS density is the number of E-TLS per unit tissue area;
[0023] Optionally, the different cell components also include one or more of the following: CD21+ cells, BCL6-positive cells, Ki-67-positive cells, and the TLS area is identified based on the stained tumor tissue pathology section image, and whether the TLS area is an E-TLS area is determined based on the immunohistochemical staining results of different cell components, and the E-TLS density feature is calculated based on the E-TLS area.
[0024] Optionally, multiple immunofluorescence techniques are used to label TLS-related cells, and based on the labeling results, the E-TLS region is identified and the E-TLS density characteristics are calculated;
[0025] Optionally, the multiple immunofluorescence technology identifies the TLS region through CD4, CD8, and CD20, determines whether the TLS region is an E-TLS region through CD21 and CD23, and calculates the E-TLS density characteristics based on the E-TLS region.
[0026] The second aspect of the present application discloses a system for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS, comprising:
[0027] Acquisition module 201: used to obtain tumor tissue pathological sections of patients with non-small cell lung cancer;
[0028] Positioning module 202: used to position the tumor infiltration edge of the tumor tissue pathological section;
[0029] Feature extraction module 203: used to extract the E-TLS density feature of the tumor invasion edge;
[0030] Decision module 204: used to judge the prognosis of patients with non-small cell lung cancer according to the E-TLS density characteristics of the tumor infiltration edge. If the E-TLS density characteristics are lower than the E-TLS density threshold, the patient's prognosis is good; if they are higher than the E-TLS density threshold, the patient's prognosis is poor.
[0031] The third aspect of the present application discloses a computer device, which includes: a memory and a processor; the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, it is used to execute the steps of the above method.
[0032] A fourth aspect of the present application discloses a computer-readable storage medium having a computer program stored thereon, wherein the computer program implements the steps of the above method when executed by a processor.
[0033] A fifth aspect of the present application discloses a computer program product, including a computer program, which implements the steps of the above method when executed by a processor.
[0034] This application has the following beneficial effects:
[0035] This study divided NSCLC tumors into three regions, explored the expression of TLS in different maturation states in the three regions of NSCLC tumors and their correlation with patient prognosis, and found that the poor prognosis of NSCLC patients was significantly correlated with the high expression of E-TLS in the IM region, and the high expression of E-TLS in the IM region may be related to the fact that CD20+B cells and CD3+T cells did not participate in the TLS maturation process. In addition, the high expression of E-TLS in the IM region may also be related to anti-tumor immunosuppression in this region. This suggests the important role of the IM region in tumor immunity, and provides a reference for a deeper understanding of the tumor immune microenvironment of NSCLC and the improvement of tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.
[0037] Figure 1 is a schematic diagram of a method flow chart provided by the first aspect of an embodiment of the present invention;
[0038] Figure 2 is a schematic diagram of a program product provided by the second aspect of an embodiment of the present invention;
[0039] Figure 3 is a schematic diagram of a computer device provided by an embodiment of the present invention;
[0040] Figure 4 is a schematic diagram of the architecture of an exemplary computing device provided by an embodiment of the present invention;
[0041] Figure 5 is a schematic diagram of a storage medium provided by an embodiment of the present invention;
[0042] Figure 6 This is a division of NSCLC patient sample areas and identification of TLS provided by an embodiment of the present invention: (A) The area enclosed by the blue line is the IT area (4×). (B) The area enclosed by the green line is the IM area (4×). (C) The area enclosed by the brown line is the PT area (4×). (D) The expression of E-TLS in the IT, IM and PT areas (100×). (E) The expression of F-TLS in the IT, IM and PT areas (100×). Note: IT is inside the tumor, IM is the invasive edge, PT is outside the tumor, F-TLS is secondary TLS, and E-TLS is primary TLS;
[0043] Figure 7 This is a difference in the density expression of TLS in different areas of the tumor provided by an embodiment of the present invention: (A) TLS expression density in the IT area and the corresponding patient frequency. (B) TLS expression density in the IM area and the corresponding patient frequency. (C) TLS expression density in the PT area and the corresponding patient frequency. (D) The density and difference of TLS in the IT, IM and PT areas. (E) The density and difference of E-TLS in the IT, IM and PT areas. (F) The density and difference of F-TLS in the IT, IM and PT areas. (G) Statistics on the proportion of patients with no TLS and the presence of E-TLS and F-TLS in the IT, IM and PT areas. Note: IT is inside the tumor, IM is the invasive edge, PT is outside the tumor, F-TLS is secondary TLS, E-TLS is primary TLS, and non-TLS is the absence of TLS. ** is P<0.01, *** is P<0.001;
[0044] Figure 8 The following is a correlation between the expression of TLS and the prognosis of NSCLC patients provided in an embodiment of the present invention: (AC) Kaplan-Meier analysis of the effect of the presence or absence of TLS in the IT, IM and PT regions on the prognosis of patients. (D) ROC curve based on the overall survival rate of NSCLC patients and the density of TLS in the IM region, with the black dot marking the optimal cutoff value. (E) Based on the optimal cutoff value obtained in (D), the patients were divided into a group with high expression of TLS in the IM region and a group with low expression of TLS in the IM region, and the difference in prognosis between the two groups of patients was analyzed. Note: IT is the inside of the tumor, IM is the invasive edge, and PT is the outside of the tumor;
[0045] Fig. 9An embodiment of the present invention provides a correlation between the expression of TLS in different maturity states in the IM region and prognosis: (A) After the ROC curve is drawn based on the overall survival rate of NSCLC patients and the E-TLS density in the IM region, the patients are divided into the IM region E-TLS high expression group and the IM region E-TLS low expression group with the optimal cutoff value as the boundary, and the prognostic differences between the two groups of patients are analyzed. (B) After the ROC curve is drawn based on the overall survival rate of NSCLC patients and the F-TLS density in the IM region, the patients are divided into the IM F-TLS high expression group and the IM F-TLS low expression group with the optimal cutoff value as the boundary, and the prognostic differences between the two groups of patients are analyzed. Note: IM is the invasive margin, E-TLS is the primary TLS;
[0046] Fig.10 It is the expression density of tumor-infiltrating immune cells in different regions provided by the embodiment of the present invention; legend: IT is the inside of the tumor, IM is the infiltration edge, and PT is the outside of the tumor. * is compared with the IT area, P<0.05; *** is compared with the IT area, P<0.001; # is compared with the IM area, P<0.05; ### is compared with the IM area, P<0.001;
[0047] Fig.11 This is a difference in expression of tumor-infiltrating immune cells between TLS+ / - groups in various regions provided by an embodiment of the present invention: (A) According to the presence or absence of TLS in the IT region, the patients were divided into the IT region TLS+ group and the IT region TLS- group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the IT region between the two groups. (B) According to the presence or absence of TLS in the IM region, the patients were divided into the IM region TLS+ group and the IM region TLS- group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the IM region between the two groups. (C) According to the presence or absence of TLS in the PT region, the patients were divided into the PT region TLS+ group and the PT region TLS- group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the PT region between the two groups. Note: IT is the inside of the tumor, IM is the infiltration edge, and PT is the outside of the tumor;
[0048] Fig.12This is a difference in expression of tumor-infiltrating immune cells between E-TLS / F-TLS groups in various regions provided by an embodiment of the present invention: (A) According to the maturity status of TLS in the IT region, the patients were divided into the E-TLS group and the F-TLS group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the IT region between the two groups. (B) According to the maturity status of TLS in the IM region, the patients were divided into the E-TLS group and the F-TLS group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the IM region between the two groups. (C) According to the maturity status of TLS in the PT region, the patients were divided into the E-TLS group and the F-TLS group, and the independent sample T test was used to analyze the density differences of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in the PT region between the two groups. Note: IT is inside the tumor, IM is the infiltration edge, PT is outside the tumor, F-TLS is secondary TLS, and E-TLS is primary TLS;
[0049] Fig.13 The present invention provides a correlation between TLS expression and tumor-infiltrating immune cells: (A) The density and difference of CD20+B cells, CD3+T cells, CD8+T cells, and CD68+ macrophages in IT, IM, and PT regions. (CE) General linear regression analysis of the correlation between CD20+B cells in IT, IM, and PT regions and the density of TLS in the corresponding regions. (FH) General linear regression analysis of the correlation between CD3+T cells in IT, IM, and PT regions and the density of TLS in the corresponding regions. (I) The bubble chart shows the correlation between TLS in different maturation states in IT, IM, and PT regions and immune cells in each region (red indicates a positive correlation coefficient, blue indicates a negative correlation coefficient, and purple indicates a correlation coefficient close to 0; the larger the circle, the more significant the correlation, and the smaller the circle, the weaker the correlation). (J) The bubble chart shows the CD47 score in IT, IM, and PT regions (the size of the circle indicates the frequency of the score). Note: IT is inside the tumor, IM is the infiltration edge, PT is outside the tumor, F-TLS is secondary TLS, and E-TLS is primary TLS. *P<0.05 compared with the IT area; ***P<0.001 compared with the IT area; ###P<0.001 compared with the IM area. DETAILED DESCRIPTION
[0050] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.
[0051] In some of the processes described in the specification and claims of the present invention and the above-mentioned figures, multiple operations that appear in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this article or executed in parallel. The sequence numbers of the operations, such as S101, S102, etc., are only used to distinguish between different operations, and the sequence numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel. It should be noted that the descriptions of "first", "second", etc. in this article are used to distinguish different messages, devices, modules, etc., do not represent the order of precedence, and do not limit the "first" and "second" to be different types.
[0052] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0053] Figure 1 The present invention provides a method for predicting the prognosis of non-small cell lung cancer based on the evaluation of tumor invasion margin E-TLS. Specifically, the method comprises the following steps:
[0054] S101: Obtain tumor tissue pathological sections from patients with non-small cell lung cancer;
[0055] In some embodiments, tumor tissue specimens are obtained from patients, and primary lung tumor tissue specimens collected by formalin fixation are subjected to FFPE (formalin fixation and paraffin embedding) and serial sectioning (5 um thickness). Ten serial sections are taken from all patients and used for staining of different immune cell indicators.
[0056] S102: locating the tumor infiltration edge of the tumor tissue pathological section;
[0057] In the tissue section observation, different tissue structures were divided into IT region (intra-tumoral region, inside the tumor), PT region (peri-tumor region, outside the tumor) and IM region (invasive margin region, i.e. the area with a width of 500um inside and outside the junction of IT region and PT region).
[0058] In some embodiments, localization to the invasive margin of the tumor is performed by observation of FFPE sections.
[0059] S103: extracting the E-TLS density feature of the tumor invasion edge;
[0060] In this study, the maturity of TLS is divided into E-TLS (early TLS) and F-TLS (follicular TLS).
[0061] There are two states of TLS: secondary / follicular TLS. E-TLS are lymphocyte aggregates dominated by CD20+ B cells and CD3+ T cells, but lack GCs (germinal centers) dominated by CD21+ FDCs (follicular dendritic cells).
[0062] In some embodiments, experienced clinicians identify E-TLS and F-TLS based on immune cell staining and calculate the E-TLS density.
[0063] In some embodiments, software is used based on computer vision to automatically identify E-TLS and calculate the E-TLS density.
[0064] S104: Determine the prognosis of a patient with non-small cell lung cancer according to the E-TLS density feature of the tumor infiltration edge. If the E-TLS density feature is lower than the E-TLS density threshold, the patient's prognosis is good; if the E-TLS density feature is higher than the E-TLS density threshold, the patient's prognosis is poor.
[0065] In some embodiments, the step of determining the E-TLS density threshold comprises:
[0066] Step 1: Obtain tumor tissue pathology sections of a patient set of non-small cell lung cancer; and obtain the overall survival of the patient set of non-small cell lung cancer;
[0067] Step 2: Locate the tumor infiltration margin of the tumor tissue pathology section;
[0068] Step 3: extracting the E-TLS density feature set of the tumor invasion edge;
[0069] Step 3: Plot a ROC curve of the relationship between the E-TLS density feature set and the overall survival period, and the E-TLS density threshold is the optimal cutoff value of the ROC curve.
[0070] In some embodiments, the E-TLS density threshold ranges from: [1.031 to 3.689].
[0071] In some embodiments, the E-TLS density threshold is 1.951.
[0072] The research on which this application is based is as follows:
[0073] Study subjects
[0074] Clinical and pathological characteristics of patients
[0075] This retrospective study included 95 patients with NSCLC who were diagnosed and underwent primary lung tumor resection at Dalian Friendship Hospital between January 2011 and November 2018. All patients were aged 18 years or older, had no previous malignant disease, and did not receive neoadjuvant chemotherapy and / or radiotherapy before surgery. Two patients were excluded due to a history of renal clear cell carcinoma and thyroid cancer. In addition, 11 patients were excluded due to insufficient evaluation of the peritumoral content. Therefore, 82 patients were included in the study cohort and further analyzed (Table 1). The study protocol was approved by the Institutional Review Board of the hospital (IRB number KY-2023(009)-001). As this was a noninterventional retrospective study, the IRB waived the informed consent. This study was conducted in accordance with the principles of the Declaration of Helsinki.
[0076] Clinical and pathological data, including age, sex, smoking history, and tumor size, were retrieved from electronic hospital records. Tumors were staged according to the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) classification and the 8th edition of the pathological staging guidelines. Follow-up information was collected by telephone survey, and the last follow-up was December 2022. A total of 80 patients were followed up, with a median follow-up time of 59.1 months. Overall survival (OS) was defined as the time from resection to death, loss to follow-up, or the last follow-up date. Recurrence-free survival (RFS) was defined as the time from surgical resection to the diagnosis of recurrence or the last follow-up.
[0077] Table 1 Clinical information of 82 NSCLC patients
[0078]
[0079]
[0080] Research Methods
[0081] Immunohistochemistry
[0082] The primary lung tumor tissue specimens collected were fixed with formalin, FFPE (formalin fixation and paraffin embedding) and serially sectioned (5 um thickness). All patients underwent 10 serial sections, which were used for staining of different immune cell indicators.
[0083] The IHC staining process is as follows: First, bake the tissue sections in an oven at about 60°C for 1 hour to fix them. Then put all tissue sections into a xylene container and soak for 10 minutes, then put them into 95% alcohol and 75% alcohol containers for 10 minutes each, rinse them repeatedly with a stream of water, and then soak and rinse them again with PBS buffer (5 minutes / time × 3 times) to dewax the tissue. Prepare antigen repair buffer by mixing 5ml EDTA + 250ml distilled water, preheat at 100°C in a microwave for 3 minutes, add the tissue section rack to be tested, and keep the temperature at about 95-98°C for 15 minutes to repair the antigen. After exposing the antigen site, cool it naturally to room temperature, and soak and rinse it again with PBS buffer (5 minutes / time × 3 times). Endogenous peroxidase is blocked by soaking it in 3% H2O2 / methanol at room temperature for 15 minutes, and the tissue sections removed are rinsed again with PBS buffer (3 minutes / time × 3 times).
[0084] Primary antibody incubation: MXB Biotechnologies' ready-to-use antibodies anti-CD8 (MAB-0021), anti-CD3 (MAB-0740), anti-CD20 (kit-0001), anti-CD21 (RMA-0811), anti-CD68 (kit-0026) and CXCL-13 (GAB-0616), and ABclonal's anti-CD47 antibody (A11382, 1:100) were incubated overnight at 4°C. Subsequently, the cells were washed with PBS for 3 minutes and incubated with secondary antibodies for 15 minutes. The cells were developed with 3,3' diaminobenzidine (DAB) for 3-10 minutes (the development time was controlled under a microscope), and then washed with PBS for 10 minutes. The sections were counterstained with hematoxylin, embedded for 20 seconds, and finally dehydrated and mounted.
[0085] A series of consecutive tissue specimens were collected from FFPE and prepared at a thickness of 5 μm. MaxVision staining was performed manually. The tissue was dewaxed and rehydrated in a gradient of ethanol to water. Antigen retrieval was achieved by autoclaving for 2 minutes and then cooling to room temperature. Endogenous peroxidase was inactivated using 0.3% H2O2 / methanol at room temperature for 15 minutes. Serial tissue sections were incubated overnight with primary monoclonal antibodies, anti-CD47 (A11382, 1:100, ABclonal) and ready-to-use antibodies from MXB Biotechnologies, including anti-CD8 (MAB-0021), anti-CD3 (MAB-0740), anti-CD20 (kit-0001), anti-CD21 (RMA-0811), and anti-CD68 (kit-0026). Subsequently, the slides were washed 3 times with PBS for 3 minutes each time and then incubated with secondary antibodies for 15 minutes. Specific signals were visualized using 3,3'-diaminobenzidine (DAB) for 3-10 min (controlled under a microscope) and then washed with PBS for 10 min. The sections were counterstained with hematoxylin for 20 s, dehydrated and mounted. Necrotic areas were excluded from the analysis.
[0086] Quantification of TLS
[0087] TLS were evaluated by one expert pathologist (SW) and two observers (SYX and XPH) who were blinded to the clinicopathological data. They were trained to identify the pathological features of TLS in whole sections containing the intratumoral (IT), invasive margin (IM), and peritumoral (PT) areas ( Figure 6 AC). The IM area was defined as 500 μm on each side of the border between tumor and normal lung tissue. TLS were identified by CD3 / CD20 staining of serial slides of whole FFPE tumor tissue sections. Patients were considered TLS positive (TLS+) if at least one TLS was observed. TLS maturation status was divided into early TLS (E-TLS) and follicle-forming TLS (F-TLS). E-TLS showed diffuse lymphocyte accumulation and scarce CD21+ cells ( Figure 6 D), while F-TLS showed follicular morphology with CD21+ follicular dendritic cells (FDC) ( Figure 6E). TLS density was calculated as the number of TLS per millimeter of tissue area in the IT, IM, and PT regions. ROC curves were constructed based on overall survival and TLS density, and the maximum Youden index was used to determine the optimal TLS density cutoff (Youden index = sensitivity + specificity - 1). Patients were then divided into high-density and low-density groups according to the TLS density in each region. Quantification of tumor-infiltrating immune cells Two observers (SYX and XPH) evaluated the density of infiltrating lymphocytes using digital slide examination. Digital images were scanned using an MVC3000 slide scanner (Mydream Electronic, Shanghai, China) and quantified using ImageJ software (NIH). Five random microscopic fields (20x magnification) were selected and captured from the IT, IM, and PT regions. Cell density was calculated as the average number of positive cells per field of view. CD47 expression To further explore the immune signature, CD47 expression was evaluated. Tumor cells express high levels of CD47 during tumorigenesis, bind to macrophage receptors and lead to immune escape. The expression rate of CD47 was calculated as the percentage of CD47-positive cells in the corresponding section area (0-100%). The staining intensity of CD47 was divided into weak (assignment = 1), moderate (assignment = 2) and strong (assignment = 3). The expression score of CD47 was calculated as follows:
[0088] CD47 score = (percentage of CD47 with weak staining × 1) + (percentage of CD47 with medium staining × 2) + (percentage of CD47 with strong staining × 3)
[0089] The score ranged from 0 to 300, with 300 points indicating 100% strong positive expression in the tumor area.
[0090] Statistical analysis Statistical analysis was performed using SPSS 26.0 (IBM) and GraphPad Prism 9 (San Diego, CA, USA). Continuous data were expressed as mean ± standard deviation (SD), and count data were expressed as median (quartile). The differences in count data were compared using t-test or Mann-Whitney U test. Chi-square test and continuity-corrected chi-square test were used to analyze categorical variables. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to determine the optimal TLS density threshold for each partition. Spearman rank correlation was used to analyze the correlation between TLS maturity and immune cells. The Kaplan-Meier method was used to plot OS and PFS curves, and the log-rank test was used to compare them. Univariate and multivariate Cox regression models were used to evaluate the prognostic risk of NSCLC patients. Statistical significance was set at P < 0.05. Based on multivariate Cox regression analysis, a nomogram including age, sex, IME-TLS, and tumor node metastasis (TNM) stage was used to predict the 1-, 3-, and 5-year overall survival probabilities of NSCLC patients.
[0091] result
[0092] (I) Expression characteristics and clinical relevance analysis of TLS
[0093] 1. Expression of TLS in different tumor regions
[0094] Overall, the TLS positivity rate reached 98.8% (81 / 82) in 82 patients, and only 1 patient's sample had no TLS observed.
[0095] The positive expression rate and expression density of TLS in different tumor areas were observed. The positive expression rate of TLS in the IT area (90.2%, 74 / 82) was significantly higher than that in the IM area (72.0%, 59 / 82) and PT area (67.1%, 55 / 82), and the average expression density of TLS in the IT area (0.45 / mm 2 ) was also significantly higher than that in the IM area (0.18 / mm 2 ) and PT area (0.16 / mm 2 ). This indicates that there are significant differences in the expression of TLS in the three regions of the tumor ( Figure 7 AC).
[0096] Then, the expression density of TLS in different mature states in different areas of the tumor was observed. Figure 7 As shown in DF, the expression of total TLS density, E-TLS density and F-TLS density in the IT area was significantly higher than that in the IM area and PT area (P<0.001).
[0097] We further explored the proportion of TLS in different maturity states in the three regions. Figure 7 G It can be seen that the proportion of F-TLS in the total TLS in the IT area (61.0%, 50 / 82) was significantly higher than that in the IM area (39.0%, 32 / 82) and PT area (40.2%, 33 / 82), P < 0.001.
[0098] In summary, the expression of TLS in the IT area of NSCLC patients is significantly increased, and the proportion of mature F-TLS with complete structure is the highest. At the same time, considering that the expression of TLS, E-TLS and F-TLS in the IT area, IM area and PT area is different, the three areas will be analyzed separately in all subsequent analyses.
[0099] 2. Correlation analysis between TLS expression in different regions and clinical characteristics of patients
[0100] We further explored the correlation between the TLS expression density in the three different regions and the clinical characteristics of the patients. As shown in Table 2, the density of TLS in the IT region was significantly correlated with the TNM stage of the patient (P = 0.002) and the presence of lymph node metastasis (P = 0.034). The density of TLS in the IM region was associated with the pathological type (P = 0.005), the presence of lymph node metastasis (P = 0.013), and smoking (P = 0.045). However, the density of TLS in the PT region was significantly correlated with gender (P = 0.001), pathological type (P = 0.000), tumor diameter (P = 0.013), smoking (P = 0.004), and P53 expression (P = 0.015).
[0101] Table 2 Correlation between TLS density and clinical characteristics of patients
[0102]
[0103]
[0104] (II) Correlation between TLS expression and patient prognosis
[0105] First, the prognostic differences between TLS+ and TLS- patients in different regions were compared. The results of Kaplan-Meier survival analysis are as follows Figure 8 As shown in AC, the presence or absence of TLS in the IT, IM and PT areas had no clear correlation with the patient's prognosis.
[0106] Secondly, the TLS expression of patients was carefully quantified according to the density, and the correlation between the TLS expression density in different regions and the patient's prognosis was observed. Considering that the TLS expression density is a continuous variable, the relationship between the density of TLS in different regions and the overall survival was first plotted as an ROC curve. The results showed that only the area under the ROC curve (AUC) corresponding to the TLS density in the IM region was >0.6 (AUC = 0.643, 95% CI: 0.521-0.764, Figure 8 D), while the AUCs of IT and PT were both <0.6, indicating that only the TLS density in the IM region was likely to be associated with the patient's prognosis. Therefore, in the IM region, the ROC curve was used to obtain the optimal cutoff value of TLS expression density, and the patients were divided into high- and low-TLS expression groups using this cutoff value. The correlation between high and low TLS expression in the IM region and prognosis was analyzed. Figure 8 As shown in E, the lower the TLS density, the better the prognosis of the patient.
[0107] Finally, based on the previous results, the TLS in the IM area was reclassified according to the different maturity states of TLS to observe its effect on the patient's prognosis. ROC curves were drawn based on the relationship between E-TLS density and F-TLS density and the patient's overall survival. The results showed that the area under the ROC curve (AUC) corresponding to E-TLS density was >0.6 (AUC = 0.633, 95% CI: 0.510-0.755, Fig. 9 A), while F-TLS density (AUC) <0.6, indicating that only E-TLS density is likely to be related to patient prognosis. Then, the optimal cutoff value of E-TLS density was obtained from the ROC curve, and the patients were divided into E-TLS high expression group and low expression group using this cutoff value. The prognosis of patients with high and low expression of E-TLS was further compared. The results showed that patients with low expression of E-TLS had a better prognosis (P=0.033, Fig. 9 B).
[0108] (III) Correlation analysis between TLS expression in different regions and at different maturation states and expression of tumor-infiltrating immune cells
[0109] TLS structures and tumor-infiltrating immune cells are both important components of the tumor immune microenvironment, and both play a vital role in tumor immunity. In different tissue sites of lung cancer, what kind of correlation exists between the two and whether there is any interaction will be discussed in this part of the study. During the analysis process, the situation of tumor-infiltrating immune cells was calculated according to the cell distribution density, and the expression of TLS was calculated separately according to whether it was expressed (TLS+ or TLS-) and the TLS expression density.
[0110] 1. Correlation analysis between TLS expression in different regions and tumor-infiltrating immune cells
[0111] First, statistical analysis was performed on the differences in the expression density of CD20+B cells, CD3+T cells, CD8+cytotoxic T cells, and CD68+macrophages in different regions. Fig.10 As shown, the expression of the four cell types in the IM region was significantly higher than that in the IT and PT regions.
[0112] Secondly, we observed whether TLS expression was correlated with immune cell density in the IT region. Fig.11 As shown in A, there was no statistical difference in the density of CD20+B cells, CD3+T cells, CD8+ cytotoxic T cells, and CD68+ macrophages between the TLS+ and TLS- groups in the IT area.
[0113] Furthermore, the expression differences of immune cells in TLS+ and TLS- in the IM region were analyzed. The results showed that the CD20+ B cells and CD3+ T cells in the IM region of TLS+ patients were significantly higher than those of TLS- patients (P=0.000 and P=0.047, Fig.11 B).
[0114] Finally, in the PT area, the number of CD20+B cells, CD3+T cells, CD8+ cytotoxic T cells, and CD68+ macrophages in TLS+ patients were significantly higher than those in TLS- patients (P=0.004, P=0.003, P=0.049, P=0.000, Fig.11 C).
[0115] 2. Correlation analysis between TLS expression at different maturity states and tumor-infiltrating immune cells
[0116] The results of the previous part have shown that the expression of TLS in different maturation states is different and has different significance for prognosis. Whether tumor-infiltrating immune cells play a role in the maturation process of TLS is worth exploring. Therefore, this part further explores the correlation between different maturation states of TLS and tumor-infiltrating immune cells.
[0117] First, the expression density of immune cells in the E-TLS group and the F-TLS group was analyzed in the IT area. Fig.12 As shown in A, the density of CD20+ B cells and CD8+ T cells in the F-TLS group was significantly higher than that in the E-TLS group (P=0.004 and P=0.024).
[0118] Secondly, the expression density of immune cells in the E-TLS group and the F-TLS group was analyzed in the IM region. As shown in 12B, no statistical difference was found in any of the four immune cells between the two groups.
[0119] Finally, the expression density of immune cells in the E-TLS group and the F-TLS group was analyzed in the PT area, and no statistical difference was found ( Fig.12 C).
[0120] 3. Correlation analysis between TLS density in different regions and tumor-infiltrating immune cells
[0121] In the previous part, the results analyzed the infiltration of different tumor-infiltrating immune cells in patients when TLS existed in different regions. Furthermore, the correlation between the TLS expression density and the tumor-infiltrating immune cell density in each sample was analyzed.
[0122] First, since CD20+B cells and CD3+T cells are the main components of TLS, the expression of the former two may affect the formation and expression of TLS. Therefore, the correlation analysis between the density of TLS expression and the density of CD20+B cells and CD3+T cells in the IT, IM and PT regions was performed. The results showed that the density of CD20+B cells was significantly correlated with the density of TLS in the corresponding regions only in the IM and PT regions (R 2 =0.31, P<0.0001; R 2 =0.53, P<0.0001; Fig.13 AC), there was no statistically significant correlation between the two in the IT area. However, the density of CD3+T cells was significantly correlated with the density of TLS in the three areas (R 2 =0.08, P = 0.0115; R 2 =0.07, P = 0.0129; R 2 =0.26, P<0.0001; Fig.13 DF).
[0123] Secondly, in order to more comprehensively evaluate the correlation between TLS expression density and the expression density of various tumor-infiltrating immune cells, Spearman correlation analysis was performed between the TLS density in different regions and at different maturity states of the tumor and the density of each immune cell. Fig.13 H shows:
[0124] In the IT area, the density of CD20+B cells was significantly correlated with the density of total TLS and F-TLS, but had no statistically significant correlation with the density of E-TLS; the density of CD3+T cells was significantly correlated with the density of total TLS, E-TLS and F-TLS; the density of CD8+T cells was significantly correlated with the density of total TLS and F-TLS, but had no statistically significant correlation with the density of E-TLS; the density of CD68+macrophages had no statistically significant correlation with the density of TLS in each maturity state.
[0125] In the IM region, the density of CD20+B cells and CD3+T cells were correlated with the density of total TLS and E-TLS, but had no statistically significant correlation with the density of F-TLS; there was no statistically significant correlation between CD8+T cells and CD68+macrophages and the density of TLS at each maturity state.
[0126] In the PT area, the density of CD20+B cells, CD3+T cells and CD8+T cells were significantly correlated with the expression density of TLS in each maturity state; the density of CD68+macrophages was significantly correlated with the total TLS density and E-TLS density, but had no statistically significant correlation with the F-TLS density.
[0127] Finally, previous studies have suggested that CD47 molecules are associated with tumor immune escape, and current studies have shown that they can be used as an effective target for tumor immunotherapy. [37,38] Therefore, in this study, we further calculated the expression scores of CD47 in different tumor regions. Fig.13 As shown in G, the expression scores of CD47 in the IT region (average score 36.34) and IM region (average score 39.02) were significantly higher than those in the PT region (average score 6.59), while there was no significant difference in the scores of CD47 between the IT region and the IM region. Further analysis found that there was no statistically significant correlation between the CD47 score and the density of TLS at each maturity state in the IT region, IM region, and PT region. (IV) Relationship between E-TLS in the IM region and overall survival
[0128] The results of the study showed that the density of TLS in the IM area and the density of E-TLS in the IM area were significantly correlated with the patient's prognosis. In order to find reliable prognostic risk predictors for NSCLC, multivariate analysis is needed to exclude the influence of confounding factors.
[0129] First, according to the overall survival of patients, the clinical characteristics of 80 patients and the expression of TLS were collected for univariate Cox regression analysis, and P<0.05 was used as the threshold to screen out factors related to prognosis. They were tumor pathological type, lymph node metastasis, tumor size, TNM stage, high or low expression of TLS in the IM area, and high or low expression of E-TLS in the IM area.
[0130] The above factors were further included in multivariate Cox regression analysis, and the results showed that low expression of E-TLS in the IM area and high TNM stage were independent risk factors for patients' overall survival (HR=1.951, 95%CI: 1.031-3.689, P=0.040; HR=2.328, 95%CI: 1.112-4.868, P=0.025, Table 3).
[0131] Table 3 Cox regression analysis based on overall survival of NSCLC patients
[0132]
[0133] discuss
[0134] This study first showed the expression of TLS in different mature states in different areas of NSCLC patient tumors. It was found that the positive rate of TLS in NSCLC patient tumor samples was very high, reaching 98.8%. Among the 82 subjects included in the study, only one patient sample was not detected with TLS. In the three areas of the divided tumor samples, the positive rate of TLS in the IT area was also significantly higher than that in the IM and PT areas. In addition, the expression density of TLS and the proportion of F-TLS in the IT area of the tumor were also significantly higher than those in the IM and PT areas. In order to explore why the positive rate and density of TLS in the IT area were significantly higher than those in the IM and PT areas, the expression of immune chemokine CXCL13, which can induce TLS formation, in the three areas of the tumor was detected. Previous studies have shown that CXCL13 can induce B cell aggregation to form TLS. In this study, the density of TLS in the IT area was high, but the expression of CXCL13 was low, indicating that the formation of TLS in this area has tended to be steady-state and the ability of CXCL13 to induce TLS is low. In the PT area, the expression of CXCL13 was significantly higher than that in the IM area, and more significantly higher than that in the IT area, indicating that the ability of CXCL13 to induce TLS was strongest in the IM area; at the same time, it was further speculated that the density of TLS in the IM and PT areas may continue to grow. The induced expression of TLS in the IT, IM and PT areas can also support the theory proposed by previous studies that immune induction gradually migrates from the tumor to the outside of the tumor during tumor development [40,41]. Therefore, this study believes that the formation and development of TLS mainly occurs at the tumor infiltration front, the immune environment inside the tumor is more stable than that around the tumor, mature TLS is abundantly expressed, and the formation of TLS tends to be steady-state.
[0135] Subsequent analysis of the correlation between TLS and clinical characteristics of patients found that patients with low TNM stage and no lymph node metastasis had higher TLS density in the IT region, suggesting that TLS accumulates in large numbers in the tumor of early NSCLC patients. The expression of TLS in the IT region is associated with clinical characteristics that are favorable to the prognosis of patients, while increased TLS density in the IM and PT regions may be associated with unfavorable prognostic factors such as tumor growth, infiltration and metastasis. Therefore, it is preliminarily considered that TLS in the IT region will have a positive impact on the prognosis of patients, while high expression of TLS in the IM and PT regions may be associated with a worse prognosis.
[0136] To further confirm the above conclusions, the effect of TLS in different areas of the tumor on the prognosis of NSCLC patients was explored next. Although many articles currently believe that high expression of TLS in tumors has a positive prognostic effect in various tumors, this study shows that TLS, regardless of its maturity state, does not affect the prognosis of patients in the IT and PT areas. However, high expression of TLS in the IM area is associated with a poor prognosis in NSCLC patients, and high expression of E-TLS in the IM area is an independent risk factor affecting the overall survival of patients. This may be because the presence of mature TLS is more conducive to improving the prognosis of patients, while immature TLS cannot function normally in the absence of germinal centers, and the increase in E-TLS means that the body's anti-tumor immune function is abnormal.
[0137] Tumor-infiltrating immune cells play an important role in TIME, forming TLS and affecting the formation of TLS. Therefore, different tumor-infiltrating immune cells were observed in different regions, and it was found that the proportion of tumor-infiltrating immune cells in the IM region was the largest, which is consistent with the findings of Zhu et al.
[45] . Because the IM region is the site where the tumor interacts with the normal tissues around the tumor, it is also the front line of tumor invasion. Therefore, the immune aggregation in the IM region reflects that the body has activated the anti-tumor immune response. However, previous studies have also suggested that tumor-infiltrating immune cells such as CD20+B cells, CD8+T cells, and macrophages are mainly highly expressed inside the tumor and are usually associated with a good prognosis of patients [8,46,47]. The inconsistency between this study and previous studies may be due to the following reasons: previous studies generally divided tumors simply into intratumoral and extratumoral areas, while the tumor infiltration edge, that is, the IM region in this study, was merged into the IT region. Therefore, when the IM region was divided from the IT region for analysis, it was shown that the expression of TLS in the IM region was the most significant. Subsequent related studies can also further verify the conclusions of this study by finely dividing the tissue sites.
[0138] Considering that the prognosis of TLS patients in the IM area is most significantly correlated, and the infiltration of tumor-infiltrating immune cells in this area is most obvious. Further analysis was performed on TLS and immune cells in the IM. The expression of CD20+B cells and CD3+T cells is most closely related to the prognosis of tumor patients and the effect of immunotherapy. Therefore, this study first observed the expression of CD20+B cells and CD3+T cells in patients with TLS+ in the IM area. The two cells were significantly highly expressed in patients expressing TLS, suggesting that the formation of TLS may be related to the enrichment of these two cells. Secondly, the density of CD20+B cells and CD3+T cells in the IM area was only significantly positively correlated with the density of E-TLS, but no significant correlation was found with the presence and density of F-TLS, suggesting that these two immune cells were not involved in the maturation of TLS. However, in the PT area, the density of CD20+B cells and CD3+T cells was higher in the tissues of patients expressing F-TLS, and was significantly positively correlated with the density of F-TLS, suggesting that these two immune cells were involved in the development and maturation of TLS in normal tissues adjacent to the cancer. Therefore, by comparing with the results of the PT area, this study believes that in the IM area, the process of CD20+B cells and CD3+T cells participating in TLS maturation is inhibited (the densities of the two cells were significantly positively correlated with E-TLS but not with F-TLS).
[0139] At the same time, this study suggests that the IM region may be in an immunosuppressive state. On the one hand, the CD47 score in the IM region was significantly increased. In previous studies, CD47, as a marker of immune-exempt cells, can be expressed by a variety of body cells such as stromal cells, red blood cells, and endothelial cells. When tumors occur, tumor cells express a large amount of CD47 and bind to the corresponding receptors of macrophages to obtain immune escape.
[37] The results of this study suggest that tumor cells in the IM region may escape immunity due to high expression of CD47, thus suggesting that the IM region may be in an immunosuppressive state.
[51] On the other hand, previous studies have found that immature TLS (E-TLS) cannot exert the anti-tumor immune function of mature TLS. Whether in the early stage of the disease or in tumor tissues after tumor immunotherapy, the formation of a large number of immature TLS (E-TLS) usually leads to the expression of a large number of immunosuppressive genes and is associated with poor prognosis of patients. [52-55] Therefore, the expression of a large amount of E-TLS in the IM region may also lead to the production of an immunosuppressive state.
[0140] In summary, this study divided NSCLC tumors into three regions, explored the expression of TLS in different maturation states in NSCLC tumors and their correlation with patient prognosis, and found that the poor prognosis of NSCLC patients was significantly correlated with the high expression of E-TLS in the IM region, and the high expression of E-TLS in the IM region may be related to the fact that CD20+B cells and CD3+T cells did not participate in the TLS maturation process. In addition, the high expression of E-TLS in the IM region may also be related to anti-tumor immunosuppression in this region. This suggests the important role of the IM region in tumor immunity, and provides a reference for a deeper understanding of the tumor immune microenvironment of NSCLC and the improvement of tumor immunotherapy.
[0141] Figure 3 is a schematic diagram of a computer device provided by an embodiment of the present invention, such as Figure 3 As shown, the device may include: one or more processors, and one or more memories; wherein the memories store computer-readable codes, and when the computer-readable codes are run by the one or more processors, the method described above may be executed.
[0142] The processor in this embodiment can be an integrated circuit chip with signal processing capabilities. The above processor can be a general-purpose processor, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA) or other programmable logic devices, discrete gates or transistor logic devices, discrete hardware components. The disclosed methods, operations and logic block diagrams in the embodiments of the present disclosure can be implemented or executed. The general-purpose processor can be a microprocessor or the processor can also be any conventional processor, etc., which can be an X86 architecture or an ARM architecture.
[0143] In general, various example embodiments of the present disclosure may be implemented in hardware or dedicated circuits, software, firmware, logic, or any combination thereof. Certain aspects may be implemented in hardware, while other aspects may be implemented in firmware or software that may be executed by a controller, microprocessor, or other computing device. When various aspects of the disclosed embodiments are illustrated or described as block diagrams, flow charts, or using some other graphical representation, it will be understood that the blocks, devices, systems, techniques, or methods described herein may be implemented in hardware, software, firmware, dedicated circuits or logic, general purpose hardware or controllers or other computing devices, or some combination thereof as non-limiting examples.
[0144] For example, the method or device according to the embodiment of the present disclosure may also be implemented by Figure 4 The architecture of the computing device 3000 shown in FIG. Figure 4As shown, the computing device 3000 may include a bus 3010, one or more CPUs 3020, a read-only memory (ROM) 3030, a random access memory (RAM) 3040, a communication port 3050 connected to a network, an input / output component 3060, a hard disk 3070, etc. The storage device in the computing device 3000, such as ROM 3030 or hard disk 3070, may store various data or files used for processing and / or communication of the method provided by the present disclosure and program instructions executed by the CPU. The computing device 3000 may also include a user interface 3080. Of course, Figure 4 The architecture shown is only exemplary and can be omitted according to actual needs when implementing different devices. Figure 4 One or more components of a computing device are shown.
[0145] The embodiment of the present invention also provides a computer-readable storage medium, such as Figure 5 As shown, it is a schematic diagram of a storage medium provided by an embodiment of the present invention, and a computer readable instruction 4010 is stored on the computer storage medium 4020. When the computer readable instruction 4010 is executed by the processor, the method according to the embodiment of the present disclosure described with reference to the above figures can be executed. The computer readable storage medium in the embodiment of the present disclosure can be a volatile memory or a non-volatile memory, or can include both volatile and non-volatile memories. The non-volatile memory can be a read-only memory (ROM), a programmable read-only memory (PROM), an erasable programmable read-only memory (EPROM), an electrically erasable programmable read-only memory (EEPROM) or a flash memory. The volatile memory can be a random access memory (RAM), which is used as an external cache. By way of example and not limitation, many forms of RAM are available, such as static random access memory (SRAM), dynamic random access memory (DRAM), synchronous dynamic random access memory (SDRAM), double data rate synchronous dynamic random access memory (DDRSDRAM), enhanced synchronous dynamic random access memory (ESDRAM), synchronous link dynamic random access memory (SLDRAM), and direct memory bus random access memory (DR RAM). It should be noted that the memory of the methods described herein is intended to include, but is not limited to, these and any other suitable types of memory. It should be noted that the memory of the methods described herein is intended to include, but is not limited to, these and any other suitable types of memory.
[0146] The present disclosure also provides a computer program product or a computer program, which implements the steps of the above method when executed by a processor, such as Figure 2 As shown, the computer program product or computer program comprises:
[0147] Acquisition module 201: used to obtain tumor tissue pathological sections of patients with non-small cell lung cancer;
[0148] Positioning module 202: used to position the tumor infiltration edge of the tumor tissue pathological section;
[0149] Feature extraction module 203: used to extract the E-TLS density feature of the tumor invasion edge;
[0150] Decision module 204: used to judge the prognosis of patients with non-small cell lung cancer according to the E-TLS density characteristics of the tumor infiltration edge. If the E-TLS density characteristics are lower than the E-TLS density threshold, the patient's prognosis is good; if they are higher than the E-TLS density threshold, the patient's prognosis is poor.
[0151] It should be noted that the flowcharts and block diagrams in the accompanying drawings illustrate the possible architecture, functions and operations of the systems, methods and computer program products according to various embodiments of the present disclosure. In this regard, each box in the flowchart or block diagram can represent a module, a program segment, or a part of a code, and the module, program segment, or a part of a code contains one or more executable instructions for implementing a specified logical function. It should also be noted that in some alternative implementations, the functions marked in the box can also occur in a different order from the order marked in the accompanying drawings. For example, two boxes represented in succession can actually be executed substantially in parallel, and they can sometimes be executed in the opposite order, depending on the functions involved. It should also be noted that each box in the block diagram and / or flowchart, and the combination of boxes in the block diagram and / or flowchart can be implemented with a dedicated hardware-based system that performs a specified function or operation, or can be implemented with a combination of dedicated hardware and computer instructions.
[0152] In general, various example embodiments of the present disclosure may be implemented in hardware or dedicated circuits, software, firmware, logic, or any combination thereof. Certain aspects may be implemented in hardware, while other aspects may be implemented in firmware or software that may be executed by a controller, microprocessor, or other computing device. When various aspects of the disclosed embodiments are illustrated or described as block diagrams, flow charts, or using some other graphical representation, it will be understood that the blocks, devices, systems, techniques, or methods described herein may be implemented in hardware, software, firmware, dedicated circuits or logic, general purpose hardware or controllers or other computing devices, or some combination thereof as non-limiting examples.
[0153] Those skilled in the art can clearly understand that, for the convenience and brevity of description, the specific working processes of the systems, devices and units described above can refer to the corresponding processes in the aforementioned method embodiments and will not be repeated here.
[0154] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.
[0155] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.
[0156] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.
[0157] The exemplary embodiments of the present disclosure described in detail above are merely illustrative and not restrictive. It should be understood by those skilled in the art that various modifications and combinations may be made to these embodiments or their features without departing from the principles and spirit of the present disclosure, and such modifications should fall within the scope of the present disclosure.
Claims
1. A method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS, characterized in that: The method comprises: S101: Obtain tumor tissue pathological sections from patients with non-small cell lung cancer; S102: locating the tumor infiltration edge of the tumor tissue pathological section; S103: extracting the E-TLS density feature of the tumor invasion edge; S104: Determine the prognosis of a patient with non-small cell lung cancer according to the E-TLS density feature of the tumor infiltration edge. If the E-TLS density feature is lower than the E-TLS density threshold, the patient's prognosis is good; if the E-TLS density feature is higher than the E-TLS density threshold, the patient's prognosis is poor.
2. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 1, characterized in that: The steps of determining the E-TLS density threshold include: Step 1: Obtain tumor tissue pathology sections of a patient set of non-small cell lung cancer; and obtain the overall survival of the patient set of non-small cell lung cancer; Step 2: Locate the tumor infiltration margin of the tumor tissue pathology section; Step 3: extracting the E-TLS density feature set of the tumor invasion edge; Step 3: Plot a ROC curve of the relationship between the E-TLS density feature set and the overall survival period, and the E-TLS density threshold is the optimal cutoff value of the ROC curve.
3. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 1, characterized in that: The 101 also obtains the TNM stage of patients with non-small cell lung cancer. The S104 is replaced by S104': the E-TLS density feature and the TNM staging are input into a classifier, and the prognosis of the non-small cell lung cancer patient is determined according to the output of the classifier.
4. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 3, characterized in that: The S103 also includes extracting immune cell features at the tumor infiltration edge, wherein the immune cell features at the tumor infiltration edge include one or more of the following: CD20+B cell density, CD8 / CD3 cell density ratio, CD3+T cell density; the S104 is inputting the E-TLS density features, TNM staging and the immune cell features at the tumor infiltration edge into a classifier, and judging the prognosis of patients with non-small cell lung cancer according to the output of the classifier.
5. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 4, characterized in that: The S102 simultaneously locates the outside of the tumor of the tumor tissue pathological section, and the S103 also includes extracting the CD20+B cell density outside the tumor; the 104 is to input the E-TLS density characteristics, TNM staging, the immune cell characteristics of the tumor infiltration edge, and the CD20+B cell density outside the tumor into a classifier, and judge the prognosis of patients with non-small cell lung cancer according to the output of the classifier.
6. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 1, characterized in that: The step of extracting the E-TLS density feature of the tumor infiltration edge includes: performing immunohistochemical staining on the tumor tissue pathology section and then scanning to obtain a stained tumor tissue pathology section image; The E-TLS density feature is obtained based on the extraction of the stained tumor tissue pathological section image; Optionally, different antibodies are used to perform immunohistochemical staining on different cell components in the tumor tissue pathology section and then scanned to obtain a stained tumor tissue pathology section image, the immunohistochemical staining is IHC staining, the different cell components include CD3+T cells and CD20+B cells, and the E-TLS area is identified according to the stained tumor tissue pathology section image and the E-TLS density feature is calculated; the E-TLS density is the number of E-TLS per unit tissue area; Optionally, the different cell components also include one or more of the following: CD21+ cells, BCL6-positive cells, Ki-67-positive cells, and the TLS area is identified based on the stained tumor tissue pathology section image, and whether the TLS area is an E-TLS area is identified based on the immunohistochemical staining results of different cell components, and the E-TLS density feature is calculated based on the E-TLS area.
7. The method for predicting the prognosis of non-small cell lung cancer based on tumor invasion margin E-TLS according to claim 6, characterized in that: Using multiple immunofluorescence technology to mark TLS-related cells, identifying the E-TLS area based on the labeling results and calculating the E-TLS density characteristics; Optionally, the multiple immunofluorescence technique obtains the TLS region through CD4, CD8, and CD20, identifies whether the TLS region is an E-TLS region through CD21 and CD23, and obtains the E-TLS density feature based on the calculation of the E-TLS region.
8. A computer device, characterized in that: The device comprises: a memory and a processor; the memory is used to store a computer program; the processor executes the computer program to implement the steps of the method according to any one of claims 1 to 7.
9. A computer-readable storage medium, characterized in that: A computer program is stored thereon, and when the computer program is executed by a processor, the steps of the method according to any one of claims 1 to 7 are implemented.
10. A computer program product, comprising a computer program, characterized in that When the computer program is executed by a processor, the steps of the method described in any one of claims 1 to 7 are implemented.
Citation Information
Patent Citations
Method for prognosis evaluation of cancer patient
CN107688092A
Marker and model construction method and system for prognosis prediction of colon cancer
CN114863993A
Application of three-level lymph structure in preparation of kidney cancer typing diagnosis or prognosis evaluation
CN116400080A
Method for nondestructively, three-dimensionally and accurately measuring tumor infiltration depth of oral squamous cell carcinoma in operation
CN116735629A
Method of diagnosing breast cancer
CN1890381A
Cited By
Scoring method of Tils
CN119205756A
